Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) EBIT Margin (2016 - 2025)

Arrowhead Pharmaceuticals' EBIT Margin history spans 16 years, with the latest figure at 15.46% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 647194.0% year-over-year to 15.46%; the TTM value through Dec 2025 reached 27.55%, up 2506543.0%, while the annual FY2025 figure was 11.86%, 1693892.0% up from the prior year.
  • EBIT Margin reached 15.46% in Q4 2025 per ARWR's latest filing, down from 17.2% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 70.24% in Q1 2025 to a low of 6456.48% in Q4 2024.
  • Average EBIT Margin over 5 years is 774.72%, with a median of 169.48% recorded in 2021.
  • Peak YoY movement for EBIT Margin: plummeted -377789bps in 2023, then skyrocketed 647194bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 230.77% in 2021, then surged by 71bps to 67.36% in 2022, then plummeted by -5608bps to 3845.25% in 2023, then plummeted by -68bps to 6456.48% in 2024, then soared by 100bps to 15.46% in 2025.
  • Per Business Quant, the three most recent readings for ARWR's EBIT Margin are 15.46% (Q4 2025), 17.2% (Q3 2025), and 596.21% (Q2 2025).